Sareum Holdings SAR.L · GBp

Its shares trade on LSE under the ticker SAR.L. It has been listed since 11 October 2004. In the fiscal year to 30 June 2020, it reported revenue of £47,204 and a net loss of £985,913. At that date it held total assets of £2.0m and shareholders' equity of £1.8m.

Sareum Holdings Plc engages in the discovery and development of drug candidates for the treatment of cancers and autoimmune diseases. The company is headquartered in Cambridge, Cambridgeshire. The company went IPO on 2004-10-11. The firm's drug programs include Checkpoint Kinase 1 (CHK1), Aurora+FLT3 Kinase and Tyrosine Kinase 2- autoimmune diseases (TYK2), Aurora+FLT3 kinase and TYK2 kinase-cancer. Its Chk1 program is the advanced program and shows potency in disease models of lung and colon cancers in combination with chemotherapy; acute myeloid leukemia (AML) and B-cell lymphoma, and head and neck cancers in combination with radiotherapy. TYK2 kinase program focuses on developing a series of TYK2 inhibitors that can be dosed orally against various autoimmune and inflammatory disorders, including psoriasis and rheumatoid arthritis. Its Aurora+FLT3 Kinase program focuses on AML and other blood cancers. Its TYK2 kinase prevents T-cell acute lymphoblastic leukemia (T-ALL) cells from proliferating by causing programmed cell death.

Figures and description from our data supplier, not checked against the company's own report.

• Dr. Stephen ParkerExecutive Chairman of the Board, since 2016£99,535
• Dr. John ReaderFounder, Chief Scientific Officer, Executive Director, since 2004£206,062
• Dr. Tim MitchellChief Operating Officer - Part Time, Executive Director, since 2004£207,271
• Dr. Michael OwenNon-Executive Director£20,000
• Mr. Clive BirchSenior Non-Executive Independent Director, Secretary£25,000

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.